Navigation Links
Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
Date:7/15/2009

seline in viral load (log10 HIV RNA) at week 48 of treatment. A key secondary efficacy endpoint is the proportion of patients with plasma HIV RNA less than 50 copies/mL at week 48 of treatment.

Atazanavir boosted by ritonavir was selected for use in this study because it is recommended as an option for first-line therapy in both the International AIDS Society and Department of Health and Human Services guidelines for antiretroviral therapy. Additionally, like vicriviroc, it is administered as a once daily dose and it has been shown to have a more favorable lipid safety profile than other drugs in the PI class.

The study is being sponsored by Schering-Plough with support from Bristol-Myers Squibb.

Vicriviroc also is being studied in two large ongoing Phase III clinical studies in treatment-experienced HIV patients. For more information about vicriviroc clinical studies, please visit www.clinicaltrials.gov, search term: vicriviroc.

Key Safety Findings with Vicriviroc

A pooled data analysis was conducted for two vicriviroc Phase II studies involving 205 treatment-experienced HIV-infected patients who continued on vicriviroc at the completion of 48 weeks of treatment in an open-label extension for each study. Patients received vicriviroc for up to 216 weeks of total treatment duration as part of an optimized antiretroviral regimen. AIDS-associated opportunistic infections and conditions were observed infrequently and sporadically. Infections involving the upper and lower respiratory tract were the only other infections or adverse events that occurred in 5 percent or more of patients. Elevations of liver enzymes and bilirubin were noted, but were not characteristic of drug-induced liver injury and were judged to be not related to vicriviroc. These infections and other adverse eve
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
2. Schering-Plough Announces Results of the Early ACS Trial
3. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
4. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
5. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
6. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
7. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
8. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
9. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
10. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... --  Evana Automation Specialists , a leading Systems Integrator ... recently received a contract to provide a robotic assembly ... solution will help error-proof the process of assembling catheter ... labor. A catheter adapter, connector and ... The robot will pick the adapter, connector and O-ring ...
(Date:9/16/2014)... , Sept. 16, 2014 On September 25 ... exhibition focusing on medical design and manufacturing - MEDTEC ... Shanghai World Expo Exhibition & Convention Center, bringing together ... and regions to showcase their latest medical-grade raw materials, ... only one week remaining for free visitor pre-registration to ...
(Date:9/16/2014)... The Lupus Foundation of America and Eli ... released results from UNVEIL: understanding the impact of lupus, ... journey and the challenges not only for those living ... study, which involved over 1,000 people with lupus and ... all aspects of life including family, work, finances, treatment ...
Breaking Medicine Technology:Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 2Evana Automation to Supply Robotic Assembly Cell to Leading Medical Device Manufacturer 3MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5
... 2, 2011 Floridians turned in nearly 5,500 pounds ... pharmacies and law enforcement offices throughout the state during ... more than doubling the amount dropped off at 38 ... Back Day, the National Association of Drug Diversion ...
... 2, 2011 What do Robert DeNiro, Hugo Chavez, Rudy ... Mandela, Colin Powell, Frank Zappa, Telly Savalas, Bill Bixby and ... answer is prostate cancer, then you would be correct. ... all diagnosed and successfully treated.  Chavez, the President of Venezuela, ...
Cached Medicine Technology:NADDI and the C.A.R.E.S. Alliance Co-Sponsor Successful Drug Take Back Day 2
(Date:9/16/2014)... magnesium sulfate is routinely given to pregnant women at ... won,t provide any long-term benefits for infants. ... pregnant women, researchers in Australia found it had no ... those children when they were assessed at between 6 ... negate the fact that the drug is helpful in ...
(Date:9/16/2014)... therapy as part of breast conservation is the ... positive (HR+) invasive breast cancer. A new study ... shows that combination may not be necessary for ... The results, which Fox Chase researchers presented at ... Meeting on Sunday, September 14, suggest that low-risk ...
(Date:9/16/2014)... Programs and policies that promote health and disease ... in savings for the US health system, according to ... spur these types of improvements, the National Quality Forum ... across the country to field test the NQF Action ... designed to assist groups working together to improve health ...
(Date:9/16/2014)... Silver Spring, Md. (PRWEB) September 16, 2014 ... University of Colorado Anschutz Medical Campus and Children’s ... 2014. PHA is the country’s leading pulmonary hypertension association ... hypertension (PH) – a disease of the lungs that affects ... heart failure. Without treatment, mean survivability is only 2.8 years. ...
(Date:9/16/2014)... By Tara Haelle ... -- A new blood test is the first objective scientific ... claims. The test measures the levels of nine genetic ... test could also determine who will respond to cognitive behavioral ... depression, and could show whether the therapy worked, Northwestern University ...
Breaking Medicine News(10 mins):Health News:Researchers Don't See Long-Term Benefits From Drug for Preemies 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:NQF Seeks Field Testing Groups for Population Health Guide 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2Health News:Blood Test Spots Adult Depression: Study 2Health News:Blood Test Spots Adult Depression: Study 3
... major medical advances improved survival , TUESDAY, ... has reduced the death rate for patients hospitalized for ... deal with these daily emergencies, a nationwide study finds. ... for Medicare patients treated for heart attacks decreased, from ...
... ACMIC reduces costs ... ... -- Corticon Technologies , the leading provider of Business Rules Management Systems (BRMS) ... gone live with an upgraded claims processing system built on Corticon BRMS. , ,For ...
... , Price of Diabetes ... , , BETHESDA, Md., Aug. ... people with diabetes has been misconstrued during recent health care ... the nation,s leading professional organization of doctors of podiatric medicine ...
... OKLAHOMA CITY, Aug. 18 Almost everyone who lives a long life ... at some point. As more Americans live into their 70s and ... tips that may delay onset, and how to decide when it is time ... August is Cataract Awareness Month, and the Oklahoma Academy of Ophthalmology (OAO) encourages ...
... maybe depressed, new U.S. survey of Internet players finds ... video gamer is not the stereotypical adolescent locked to ... a new U.S. survey, are 35-year-old adults, many of ... , The surprising findings also show that the health ...
... ... application called Med Records to Go(tm) , that stores electronic medical ... hospital or medical clinic admissions. Introduced by the Vital Record Corporation ... record and store personal health information and external documents for emergency viewing ...
Cached Medicine News:Health News:Hospitals Reduce Heart Attack Deaths 2Health News:Hospitals Reduce Heart Attack Deaths 3Health News:American Community Mutual Insurance Company (ACMIC) Selects Corticon 2Health News:American Community Mutual Insurance Company (ACMIC) Selects Corticon 3Health News:American Community Mutual Insurance Company (ACMIC) Selects Corticon 4Health News:American Podiatric Medical Association Corrects President's Misstatement on Foot Amputation Costs 2Health News:What Oklahomans Should Know About Cataract Surgery 2Health News:What Oklahomans Should Know About Cataract Surgery 3Health News:Video Gamers Older Than You Think 2Health News:Video Gamers Older Than You Think 3Health News:Video Gamers Older Than You Think 4Health News:"Med Records to Go" Stores Document and Image Files of Medical Facilities for Emergency Viewing 2Health News:"Med Records to Go" Stores Document and Image Files of Medical Facilities for Emergency Viewing 3
... cervical spine manipulation. Prevent dental and soft ... effective alternative to X-ray. Light-guided intubation is ... tissues in the neck. This technique takes ... trachea relative to the esophagus. A well-defined, ...
Bivona® stylets are manufactured of malleable stainless steel wire. The length can be adjusted by sliding the attached silicone stopper. The Blue Line® tracheal tube introducer (bougie) is de...
Bivona® stylets are manufactured of malleable stainless steel wire. The length can be adjusted by sliding the attached silicone stopper. The Blue Line® tracheal tube introducer (bougie) is de...
All endotracheal accessories are designed to ensure your technique. The Blue Line® intubation stylets feature a satin-smooth coating and are available in three sizes....
Medicine Products: